Apparently... A recent report from Transparency Market Research predicted a solid 8.5% compound annual growth rate (CAGR) for the sleep apnea devices market, where ResMed is a major player. Researchers believe government efforts to regulate sleep disorders, improved diagnostic processes, and aging global populations will drive market growth. In addition, Zacks Equities Research recently highlighted ResMed as a top momentum stock, citing an ongoing uptrend combined with strong earnings fundamentals

Nice work @Remorhaz I tried to find a reason for the SP jump, but came up empty handed.

Feeling glad that I got on board late last year and bought a little more on a downturn recently. Got to celebrate these little wins.

NEW 52 Week High - in the face of the that "$77b morning bloodbath"...

Shows how strong the result was and that the drug threat is being seen more as an opportunity for RMD.

Glad I held in the recent dip, would have been easy to take profits having bought in November last year.

Disc: I own RL

As my largest holding my some distance after the departure of ALU, I more than welcome it!

New 52w high today...you love to see it!